This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CaptureRx Co-founder Steps Down As Its President To Run The Washington, DC Based Non-Profit 340B Best Practices User Group - Medicine Access & Compliance Coalition™

WASHINGTON, Sept. 19, 2013 /PRNewswire/ -- In an effort to maintain integrity and focus on the initiatives of the Medicine Access & Compliance Coalition™, also known as MACC, Edward Gilmartin, co-founder of one of the nation's largest 340B administrators, CaptureRx®, has temporarily stepped down as its president as of September 9 th.  Although Mr. Gilmartin may not be managing day-to-day operations at CaptureRx®, he will be working in a consultative fashion on broad concepts and industry trends.

MACC was recently launched in late July of this year and is the first and single largest 340B drug program user group of its kind to voluntarily submit to self-examination through peer and industry review, seeking constructive input from drug manufacturers, legislators and other advocacy groups to produce and promote recommended best practices. MACC also has the distinction of being one of the first groups to include joint Federally Qualified Health Center (FQHC) and hospital leadership, with its co-chairs including the Honorable Billy Tauzin, former U.S. Congressman and past President of the Pharmaceutical Research and Manufacturers of America (PhRMA), and Dean Germano, CEO of Shasta Community Health Center of Redding, California.

Since MACC's formation, it has established offices in Washington, DC, and hired an Associate Director, who will manage MACC's daily functions and policy initiatives along with Mr. Gilmartin, who will also be working and living in DC. 

This Fall, MACC will be focused on creating a set of standards and 340B best practices that its members can follow for the newly created MACC Certification Program. These "MACC Standards" will be developed and approved by a Standards Review Board comprised of MACC Covered Entity Members and outside stakeholders to include pharma, bio, PBM, chain and independent pharmacy vendors, to name a few.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 0.00%
FB $99.54 -0.21%
GOOG $677.65 -0.75%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs